The usefulness of sulphasalazine for patients with ulcerative colitis refractory to mesalazine

The usefulness of sulphasalazine for patients with ulcerative colitis refractory to mesalazine - The usefulness of sulphasalazine for patients with ulcerative colitis refractory to mesalazine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021615

Enrollment

Registered

2016-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: From April 2010 to August 2015, 316 UC patients who had been treated at Kitano hospital were analyzed, retrospectively. Out of 316 UC patients, 32 (10.1%) with mesalazine-refractory UC who were treated with SASP were enrolled in this study. Mesalazine-refractory UC was defined as sustaining active-UC despite treatment with full-dose of oral mesalazine. The diagnosis of UC was confirmed by endoscopic and pathologic findings.

Exclusion criteria

Exclusion criteria: Exclusion criteria was defined as other than taht above.

Design outcomes

Primary

Measure	Time frame
The primary outcome was the induction-remission rate of UC patients refractory to mesalazine after initiating treatment with SASP.	—

Countries

Japan

Contacts

Public ContactTakuya Yoshino

Kitano Hospital Digestive Disease Center

t-yoshino@kitano-hp.or.jp06-6312-1221

Outcome results